Demant Stock - analyst targets move higher after Danske Bank call
22.06.2026 - 09:38:26 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/22/2026, 09:34 CET. Details in the imprint.
Demant (DK0010268440) sits in the analyst spotlight after Danske Bank lifted its price target and reiterated a positive call on the Danish hearing-care group, according to a broker note summary dated 06/21/2026. The move feeds into Monday's broader look at valuation, earnings expectations and sector positioning.
All news and analysis on Demant stock
Background reports, ad hoc releases and price data give a fuller picture of how Demant is positioned in the global hearing-care market.
Danske Bank lifts its target
Danske Bank has raised its price target on Demant shares to DKK 270 from DKK 230 and reiterated a Buy rating, according to a broker summary on MarketScreener referencing a research note published on 06/21/2026. The MarketScreener broker news item describes Demant as the world's second-largest producer of audio products and highlights growth in hearing care and custom hearing aids.
The DKK 270 target implies upside from Demant's recent trading range on the Copenhagen exchange and signals that Danske Bank remains constructive on the earnings trajectory. The broker note focuses on structural demand for hearing-care products and the company's strong clinic footprint in key markets.
How consensus is shaping up
Against this backdrop, the broader analyst consensus on Demant remains supportive, with several major houses rating the stock at Buy or equivalent, according to aggregated data from sell-side surveys. These surveys show expectations for mid-single-digit organic revenue growth over the next twelve months.
Operating margin is projected to expand gradually as higher-margin premium hearing aids and diagnostics scale, while management continues to invest in R&D. Analysts also monitor currency moves, given Demant's sizable exposure to the US dollar and euro through its international clinic network.
What the company sells
Demant generates most of its revenue from hearing-care products and tailor-made hearing aids, sold under brands such as Oticon, Bernafon, Philips and Sonic, alongside diagnostic equipment like audiometers under the Maico and Interacoustics labels. The group operates clinics under names including HearingLife and Audika, focusing on fitting and follow-up services.
Where the stock trades today
Demant shares (DK0010268440) trade on Nasdaq Copenhagen at DKK 385.60 as of 06/22/2026, 09:34 CET.
Key facts on Demant stock
- Company: Demant A/S
- ISIN: DK0010268440
- WKN: 894859
- Ticker: DEMANT
- Venue: Nasdaq Copenhagen
- Price (as of 06/22/2026, 09:34 CET): 385.60 DKK
- Market cap: 216,000,000,000 DKK (as of 06/22/2026)
- Sector / Industry: Health Care - Medical Devices & Equipment
- Index membership: OMX Copenhagen 25
- Next earnings date: 08/14/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
